The Mechanism And Progress Of Denosumab For Malignant Tumour Of Bone Metastasis

Bone is the common metastasis location of solid tumors. It always reduces the quality of life of advanced cancer patients by bone pain and skeletal-related events (SRE), or even directly threats to the life. There are various methods of treatments for bone metastases, including drugs, radiotherapy,surgical therapy and molecular targeted therapy. The monoclonal antibody of receptor activator of nuclear factor kB ligand (RANKL) can increase bone mineral density (BMD) and reduce the effect of SREs,So far it mainly used in the treatment of metastatic bone tumors, but its application in the early prevention of bone metastases or even the prevention of the formation of tumor seems like more and more important. This article mainly discusses the mechanism and progress of denosumab for malignant tumor of bone metastasis.